S. Gail Eckhardt, M.D. Professor and Division Head Medical Oncology Education: University of Texas Medical Branch, Galveston, TX  University of Colorado Denver School of Medicine Division of Medical Oncology Tel: (303) 724-3808 Fax: (303) 724-3892 e-mail: gail.eckhardt@uchsc.edu

Bio
S. Gail Eckhardt, MD is Professor and Head of the Division of Medical Oncology at the University of Colorado at Denver and Health Sciences Center where she also holds the Stapp/Harlow Endowed Chair for Cancer Research.

After graduating from the University of Texas Medical Branch in Galveston, Dr. Eckhardt completed her internship and residency at the University of Virginia Medical Center. After a post-doctoral fellowship at the Scripps Research Foundation, she completed her training in medical oncology at the University of California at San Diego. Following fellowship, Dr. Eckhardt joined the faculty of the Cancer Therapy and Research Center, Institute for Drug Development in San Antonio, Texas where she held the position of Associate Director of Clinical Research. In 1999, Dr. Eckhardt joined the faculty of the University of Colorado to set up a Phase I program, and in 2004 became the Director of the Developmental Therapeutics Program in the Cancer Center.

Dr. Eckhardt has served on numerous committees/study sections, including the ASCO Molecular Oncology Task Force, the ASCO Board of Directors, the FDA Oncology Drugs Advisory Committee, and the NCI Developmental Therapeutics Study Section. She is also a member of two NCI Steering Committees: Gastrointestinal and Investigational Drugs. In addition, Dr. Eckhardt has been an Associate Editor of Clinical Cancer Research, the Journal of Clinical Oncology, and Investigational New Drugs.

Research
Dr. Eckhardt is the Principal Investigator on three NIH grants involving early clinical trials, mentoring, and colorectal cancer research and has conducted numerous phase I and II clinical trials. She has published over 70 manuscripts and serves on numerous advisory boards. Her area of interest is in the preclinical and clinical development of combinations of molecularly targeted compounds, with a laboratory focus on colorectal cancer.